日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach

更正:利用ExDNA实现癌症中Exatecan的精准递送:一种新型抗体-药物偶联物方法

Ianniello, Zaira; Lu, Huimei; Quijano, Elias; Colón-Ríos, Daniel A; Rackear, Madison; Bommireddy, Venu; Ludwig, Dale L; Shen, Zhiyuan; Glazer, Peter M

Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach.

利用 ExDNA 实现癌症中精准的依沙替康递送:一种新型抗体药物偶联物方法。

Ianniello Zaira, Lu Huimei, Quijano Elias, Colón-Ríos Daniel A, Rackear Madison, Bommireddy Venu, Ludwig Dale L, Shen Zhiyuan, Glazer Peter M

Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer.

系统性地施用一种 RNA 结合和细胞穿透抗体,将治疗性 RNA 靶向应用于多种小鼠癌症模型

Quijano Elias, Martinez-Saucedo Diana, Ianniello Zaira, Pinto-Medici Natasha, Rackear Madison, Chen Haoting, Lola-Pereira Luiz, Liu Yanfeng, Hegan Denise, Shan Xinning, Tseng Robert, Yugawa Deanne, Chowdhury Sumedha, Khang Minsoo, Singh Jay P, Abdullah Rashed, Azhir Perisa, Kashima Soki, Woods Wendy S, Gosstola Nicholas, Turner Bruce C, Squinto Stephen, Ludwig Dale L, Bindra Ranjit S, Robert Marie E, Braun David A, Perez Pinera Pablo, Saltzman W Mark, Escobar-Hoyos Luisa F, Glazer Peter M

Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

加速器生产的Ac-225中Ac-227的剂量学影响,用于血液系统恶性肿瘤患者的α发射体放射性药物治疗:药代动力学模型分析

Sgouros, George; He, Bin; Ray, Nitya; Ludwig, Dale L; Frey, Eric C

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy

采用靶向CD45抗体放射性偶联物进行靶向淋巴细胞清除,作为过继细胞治疗前的一种新型预处理方案。

Dawicki, Wojciech; Allen, Kevin J H; Garg, Ravendra; Geoghegan, Eileen M; Berger, Mark S; Ludwig, Dale L; Dadachova, Ekaterina

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

更正:拮抗剂抗PD-L1单克隆抗体LY3300054的发现和临床前表征

Li, Yiwen; Carpenito, Carmine; Wang, George; Surguladze, David; Forest, Amelie; Malabunga, Maria; Murphy, Mary; Zhang, Yiwei; Sonyi, Andreas; Chin, Darin; Burtrum, Douglas; Inigo, Ivan; Pennello, Anthony; Shen, Leyi; Malherbe, Laurent; Chen, Xinlei; Hall, Gerald; Haidar, Jaafar N; Ludwig, Dale L; Novosiadly, Ruslan D; Kalos, Michael

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

一项针对复发或难治性黑色素瘤患者的抗TYRP1单克隆抗体IMC-20D7S的开放标签、剂量递增I期研究

Khalil, Danny N; Postow, Michael A; Ibrahim, Nageatte; Ludwig, Dale L; Cosaert, Jan; Kambhampati, Siva Rama Prasad; Tang, Shande; Grebennik, Dmitri; Kauh, John Sae Wook; Lenz, Heinz-Josef; Flaherty, Keith T; Hodi, F Stephen; Lawrence, Donald P; Wolchok, Jedd D

Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis

靶向胰岛素样生长因子I受体的抗体可通过抑制肿瘤增殖和血管生成,增强多发性骨髓瘤对化疗的抗肿瘤反应。

Wu, Kai-Da; Zhou, Li; Burtrum, Douglas; Ludwig, Dale L; Moore, Malcolm A S